Apyx Medical (APYX) Loss Narrowing In Q4 2025 Tests Bearish Earnings Narratives

Apyx Medical (APYX) just closed out FY 2025 with fourth quarter revenue of US$19.2 million and a basic EPS loss of US$0.03, alongside net income excluding extra items of a US$1.3 million loss. Over the last six reported quarters in this dataset, the company has seen quarterly revenue range from US$9.4 million to US$19.2 million, while basic EPS moved between a loss of US$0.14 and a loss of US$0.03, and trailing twelve month revenue most recently sat at US$52.8 million against an annual net loss of US$11.2 million. For investors, the latest print highlights a business that is generating meaningful top line while still working through loss making margins.

See our full analysis for Apyx Medical.

With the headline numbers on the table, the next step is to compare these results with the most common narratives around Apyx Medical to see which storylines the data supports and which ones it pushes back on.

See what the community is saying about Apyx Medical

Losses Narrow, But Trailing Twelve Month Net Loss Still Above US$11 Million

• On a trailing twelve month basis, Apyx Medical reported revenue of US$52.8 million and a net loss excluding extra items of US$11.2 million, compared with quarterly losses that ranged from US$4.7 million a year ago to US$1.3 million in the latest quarter.
• Analysts with a more cautious view point to trailing losses that have grown by about 5.8% per year over the past five years and forecast average earnings declines of 16.8% per year over the next three years. This sits in clear tension with the recent step down in quarterly net loss from US$4.7 million in Q3 2024 to US$1.3 million in Q4 2025.
  • Critics highlight that even with Q4 2025 loss at US$1.3 million, the trailing twelve month loss of US$11.2 million still reflects a business that is far from break even and is expected to remain unprofitable over the next three years.
  • At the same time, the move from basic EPS of a US$0.14 loss in Q3 2024 to a US$0.03 loss in Q4 2025 shows the recent quarterly run rate is less severe than the longer term trend that bearish investors focus on.

Stay alert to how quickly the loss profile changes from here, because bears are anchoring on much steeper long term earnings decline assumptions than the latest quarter alone might suggest. 🐻 Apyx Medical Bear Case

Revenue Forecast Around 14.7% Growth Creates Tug Of War With Earnings Risks

• The dataset shows trailing twelve month revenue at US$52.8 million and a revenue forecast of about 14.7% growth per year over the next three years, even though earnings are expected to decline by an average of 16.8% per year over the same period.
• Supporters of the bullish narrative argue that AYON and Renuvion adoption, plus demand from patients on GLP 1 drugs, can support higher procedure volumes and recurring consumable revenue. The recent move from quarterly revenue of US$9.4 million in Q1 2025 to US$19.2 million in Q4 2025 gives some numerical backing to that growth focus while still leaving the profitability concerns raised by the forecasts unresolved.
  • Backers of the growth story point to the way integrated platforms like AYON, which combine fat removal, contouring and tissue contraction in one system, are intended to increase handpiece usage per installed system. This would help support the forecast 14.7% revenue growth rate if procedure volumes stay strong.
  • At the same time, the fact that analysts are not forecasting profitability within the next three years, even on this growth profile, is a key tension for bulls who are counting on operating leverage from higher revenue to work gradually through the income statement.

If you are weighing that growth story against the earnings drag, it can be helpful to see how bullish investors connect the current numbers to their longer term expectations. 🐂 Apyx Medical Bull Case

Valuation Sits Between Peers While Trading Below DCF Fair Value

• Apyx Medical is described as trading on a P/S of 2.7x, above the peer average of 1.7x but slightly below the US Medical Equipment industry average of 2.9x, and the shares at US$3.45 are shown as about 46.6% below a DCF fair value estimate of US$6.46.
• Analysts with a balanced narrative see mixed signals here, because the higher P/S than peers aligns with a revenue growth profile of about 14.7% a year. Yet the stock also screens as materially below both the US$6.00 analyst price target and the US$6.46 DCF fair value, which suggests the market is heavily discounting the risk of continued losses that are currently running at US$11.2 million on a trailing twelve month basis.
  • On one side, the revenue forecast and the current P/S below the broader industry average give some numerical justification for investors who focus on top line expansion and are comfortable with paying more than peer multiples.
  • On the other,Next Steps

    To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Apyx Medical on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

    With the mix of growth hopes and ongoing losses in mind, it is worth looking through the numbers yourself and deciding how comfortable you feel with that balance. If you want a clear snapshot of what the market currently sees as the balance of positives and negatives, take a look at the 2 key rewards and 2 important warning signs.

    See What Else Is Out There

    Apyx Medical is still carrying a trailing twelve month net loss of US$11.2 million, with analysts not expecting profitability over the next three years.

    If that ongoing loss profile makes you want something steadier, now is a good moment to check out 68 resilient stocks with low risk scores that aim to prioritise resilience over uncertainty.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com